Urokinase-type plasminogen activator inhibits amyloid-β neurotoxicity and fibrillogenesis via plasminogen

Journal of Neuroscience Research

Volumn 70, Issue 2, 2002, Pages 249-255

  Tucker, H Michael ^a   Kihiko Ehmann, Muthoni ^a   Estus, Steven ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b NONE   (United States)

Author keywords

Alzheimer's disease; Plasmin; Proteolysis; uPA

Indexed keywords

AMYLOID BETA PROTEIN; PLASMINOGEN; UROKINASE;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CHROMOSOME 10; CONTROLLED STUDY; GENE LOCUS; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN INDUCTION; RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; CELL SURVIVAL; CELLS, CULTURED; CHROMOSOMES, HUMAN, PAIR 10; DRUG THERAPY, COMBINATION; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MACROMOLECULAR SUBSTANCES; MICROSCOPY, ELECTRON; NEURONS; PLASMINOGEN; PROTEIN BINDING; RATS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0037107974     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.10417     Document Type: Article

References (44)

1. Akiyama H, Ikeda K, Kondo H, Kato M, McGeer PL. 1993. Microglia express the type 2 plasminogen activator inhibitor in the brain of control subjects and patients with Alzheimer's disease. Neurosci Lett 164:233-235.
2. Andreasen PA, Egelund R, Petersen HH. 2000. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57:25-40.
3. Baranes D, Lederfein D, Huang YY, Chen M, Bailey CH, Kandel ER. 1998. Tissue plasminogen activator contributes to the late phase of LTP and to synaptic growth in the hippocampal mossy fiber pathway. Neuron 21:813-825.
4. Bertram L, Blacker D, Mullin K, Keeney D, Jones J, Basu S, Yhu S, McInnis MG, Go RC, Vekrellis K, Selkoe DJ, Saunders AJ, Tanzi RE. 2000. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science 290:2302-2303.
5. Bonfoco E, Krainc D, Ankarcrona M, Nicotera P, Lipton SA. 1995. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci USA 92:7162-7166.
6. Brewer GJ, Torricelli JR, Evege EK, Price PJ. 1993. Optimized survival of hippocampal neurons in B27-supplemented neurobasal, a new serum-free medium combination. J Neurosci Res 35:567-576.
7. Bugge TH, Flick MJ, Daugherty CC, Degen JL. 1995. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 9:794-807.
8. Bugge TH, Kombrinck KW, Flick MJ, Daugherty CC, Danton MJ, Degen JL. 1996. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell 87:709-719.
9. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord JJ, Collen D, Mulligan RC. 1994. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368:419-424.
10. Chen ZL, Strickland S. 1997. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell 91:917-925.
11. Chesneau V, Vekrellis K, Rosner MR, Selkoe DJ. 2000. Purified recombinant insulin-degrading enzyme degrades amyloid beta-protein but does not promote its oligomerization. Biochem J 351(Pt 2):509-516.
12. Degen JL. 1999. Hemostatic factors and inflammatory disease. Thromb Haemost 82:858-864.
13. Ertekin-Taner N, Graff-Radford N, Younkin LH, Eckman C, Baker M, Adamson J, Ronald J, Blangero J, Hutton M, Younkin SG. 2000. Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science 290:2303-2304.
14. Estus S, Tucker HM, van Rooyen C, Wright S, Brigham E, Wogulis M, Rydel R. 1997. Aggregated amyloid-α protein induces cortical neuronal apoptosis and concomitant "apoptotic" pattern of gene induction. J Neurosci 17:7736-7745.
15. Exley C, Korchazhkina OV. 2001. Plasmin cleaves Abeta42 in vitro and prevents its aggregation into beta-pleated sheet structures. Neuroreport 12:2967-2970.
16. Forloni G, Chiesa R, Smiroldo S, Verga L, Salmona M, Tagliavini F, Angeretti N. 1993. Apoptosis mediated neurotoxicity induced by chronic application of β amyloid fragment 25-35. Neuroreport 4:523-526.
17. Gschwind M, Huber G. 1995. Apoptotic cell death induced by β-amyloid1-42 peptide is cell type dependent. J Neurochem 65:292-300.
18. Henkin J, Marcotte P, Yang HC. 1991. The plasminogen-plasmin system. Progr Cardiovasc Dis 34:135-164.
19. Hosomi N, Lucero J, Heo J, Koziol J, Copeland B, Zoppo G. 2001. Rapid differentioal endogenous plasminogen activator expression after acute middle cerebral artery occlussion. Stroke 32:1341-1348.
20. Howell S, Nalbantoglu J, Crine P. 1995. Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism. Peptides 16:647-652.
21. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-Aizawa Y, Saido TC. 2000. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 6:143-150.
22. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC. 2001. Metabolic regulation of brain Abeta by neprilysin. Science 292:1550-1552.
23. Kim YH, Park JH, Hong SH, Koh JY. 1999. Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator. Science 284:647-650.
24. Kreis TE. 1987. Microtubules containing detyrosinated tubulin are less dynamic. EMBO J 6:2597-2606.
25. Loo DT, Copani A, Pike CJ, Whittemore ER, Walencewicz AJ, Cotman CW. 1993. Apoptosis is induced by β-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci USA 90:7951-7955.
26. Madani R, Hulo S, Toni N, Madani H, Steimer T, Muller D, Vassalli JD. 1999. Enhanced hippocampal long-term potentiation and learning by increased neuronal expression of tissue-type plasminogen activator in transgenic mice. EMBO J 18:3007-3012.
27. Mukherjee A, Song E, Kihiko-Ehmann M, Goodman JP, Jr., Pyrek JS, Estus S, Hersh LB. 2000. Insulysin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques. J Neurosci 20:8745-8749.
28. Myers A, Holmans P, Marshall H, Kwon J, Meyer D, Ramic D, Shears S, Booth J, DeVrieze FW, Crook R, Hamshere M, Abraham R, Tunstall N, Rice F, Carty S, Lillystone S, Kehoe P, Rudrasingham V, Jones L, Lovestone S, Perez-Tur J, Williams J, Owen MJ, Hardy J, Goate AM. 2000. Susceptibility locus for Alzheimer's disease on chromosome 10. Science 290:2304-2305.
29. Pike C, Walencewicz A, Glabe C, Cotman C. 1991. In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res 563:311-314.
30. Pittman RN, DiBenedetto AJ. 1993. PC12 cells overexpressing tissue plasminogen activator regenerate neurites to a greater extent and migrate faster than control cells in complex extracellular matrix. J Neurochem 64:576-575.
31. Qiu WQ, Ye Z, Kholodenko D, Seubert P, Selkoe DJ. 1997. Degradation of amyloid beta-protein by a metalloprotease secreted by microglia and other neural and nonneural cells. J Biol Chem 272:6641-6646.
32. Salles F, Strickland S. 2002. Localization and regulation of the tissue plasminogen activator system in the hippocampus. J Neurosci 22:2125-2134.
33. Seeds NW, Basham ME, Haffke SP. 1999. Neuronal migration is retarded in mice lacking the tissue plasminogen activator gene. Proc Natl Acad Sci USA 96:14118-141223.
34. Selkoe DJ. 2001. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81:741-766.
35. Shirotani K, Tsubuki S, Iwata N, Takaki Y, Harigaya W, Maruyama K, Kiryu-Seo S, Kiyama H, Iwata H, Tomita T, Iwatsubo T, Saido TC. 2001. Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases. J Biol Chem 6:6.
36. Simmons LK, May PC, Tomaselli KJ, Rydel RE, Fuson KS, Brigham EF, Wright S, Lieberburg I, Becker GW, Brems DN. 1994. Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. Mol Pharmacol 45:373-379.
37. Sutton R, Keohane ME, VanderBerg SR, Gonias SL. 1994. Plasminogen activator inhibitor-1 in the cerebrospinal fluid as an index of neurological disease. Blood Coagul Fibrinolysis 5:167-171.
38. Tsirka SE, Rogove AD, Strickland S. 1996. Neuronal cell death and tPA. Nature 384:123-124.
39. Tsirka SE, Rogove AD, Bugge TH, Degen JL, Strickland S. 1997. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci 17:543-552.
40. Tucker HM, Kihiko ME, Caldwell JN, Wright S, Kawarabayashi T, Price D, Scheff S, McGillis JP, Rydel RE, Estus S. 2000a. Amyloid-beta activates and is degraded by the plasmin system. J Neurosci 20:3937-3946.
41. Tucker HM, Kihiko-Ehmann M, Wright S, Rydel RE, Estus S. 2000b. Tissue plasminogen activator requires plasminogen to modulate amyloidbeta neurotoxicity and deposition. J Neurochem 75:2172-2177.
42. Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, Rosner MR, Selkoe DJ. 2000. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci 20:1657-1665.
43. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA. 1998. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 4:228-231.
44. Zhuo M, Holtzman DM, Li Y, Osaka H, DeMaro J, Jacquin M, Bu G. 2000. Role of tissue plasminogen activator receptor LRP in hippocampal long-term potentiation. J Neurosci 20:542-549.